8-K: Dentsply Sirona Reports Q4 2025, FY 2025 Results & 2026 Outlook

Dentsply Sirona announced Q4 2025 net sales growth and adjusted EPS, alongside a restructuring plan, dividend elimination, and a 2026 outlook.

Summary

• Q4 2025 net sales reached $961 million, an increase of 6.2% (2.5% in constant currency) compared to Q4 2024.
• The company reported a Q4 2025 net loss of ($146) million and diluted loss per share of ($0.74), primarily due to ($144) million in goodwill and intangible impairments, net of tax.
• Q4 2025 adjusted EPS was $0.27, an increase from $0.26 in Q4 2024.
• Full year 2025 net sales were $3,680 million, a decrease of (3.0%) (4.3% in constant currency) from FY 2024.
• Full year 2025 reported net loss was ($598) million and diluted loss per share was ($3.00).
• Full year 2025 adjusted EPS was $1.60, a decrease from $1.67 in FY 2024.
• The company provided a full year 2026 outlook, projecting net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.
• A restructuring initiative was announced, expected to redirect approximately $120 million annually into the Return-to-Growth Action Plan, focusing on innovation, clinical education, and sales team education.
• A new capital allocation strategy was initiated, eliminating the quarterly dividend to redeploy capital towards debt retirement and share repurchases.
• New agreements were established with Patterson Dental, Benco Dental, Burkhart Dental Supply, and A-dec.
• Dentsply Sirona launched the Surity Female External Catheter, entering a new market category in the U.S.
• Three new members were appointed to the Board of Directors: James Forbes, Brian McKeon, and Don Zurbay.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a transitional period for Dentsply Sirona, marked by strategic restructuring and capital reallocation aimed at long-term growth, but offset by significant impairments and a full-year sales decline.

Positives

• Q4 2025 net sales increased 6.2% (2.5% constant currency), showing positive momentum.
• Q4 2025 adjusted EPS increased to $0.27 from $0.26 year-over-year.
• Adjusted EBITDA for Q4 2025 grew 5.3% to $135 million.
• The announced restructuring initiative is anticipated to generate approximately $120 million in annualized cost savings.
• The new capital allocation strategy, focusing on debt retirement and share repurchases, aims to strengthen the balance sheet and accelerate long-term shareholder value.
• Established new agreements with key dental distributors (Patterson Dental, Benco Dental, Burkhart Dental Supply, and A-dec) to strengthen commercial performance.
• Launched the Surity Female External Catheter, marking entry into a new U.S. market category.
• The appointment of three new Board members brings significant financial and industry expertise to the company.
• Operating cash flow in Q4 2025 increased to $101 million from $87 million in Q4 2024.
• Free cash flow in Q4 2025 increased to $60 million from $36 million in Q4 2024.

Negatives

• Q4 2025 reported a net loss of ($146) million and diluted loss per share of ($0.74), driven by significant impairment charges.
• Goodwill and intangible asset impairments totaled ($144) million, net of tax, in Q4 2025.
• Full year 2025 net sales decreased (3.0%) to $3,680 million, indicating a decline over the year.
• Full year 2025 reported a net loss of ($598) million and diluted loss per share of ($3.00).
• Full year 2025 adjusted EPS decreased (4.6%) to $1.60.
• The quarterly cash dividend has been eliminated, impacting income-focused shareholders.
• Full year operating cash flow in 2025 decreased significantly to $235 million from $461 million in 2024.
• Full year 2025 free cash flow decreased to $104 million from $281 million in 2024.
• Goodwill and intangible asset impairments were attributed to lower-than-expected volumes and lowered near-term forecasts, particularly in the United States.

Risks

• Forward-looking statements are subject to numerous assumptions, risks, uncertainties, and other factors that could cause actual results to differ materially from those described.
• Risks include those detailed in Part I, Item 1A, Risk Factors of the Company's most recent Annual Report on Form 10-K, and any updating information or other factors described in the Company’s other filings with the Securities and Exchange Commission (SEC).
• It is not possible to predict or identify all potential risks or uncertainties associated with an investment in the Company.

Future Outlook

For the full year 2026, Dentsply Sirona expects net sales to be in the range of $3.5 billion to $3.6 billion and adjusted EPS to be in the range of $1.40 to $1.50. This outlook incorporates management's current expectations regarding tariffs and trade policies.

Management Comments

• "We delivered results in line with our expectations this quarter while making meaningful progress against our clear, focused priorities and strengthening execution across the business."
• "In 2026, we are acting with urgency and accountability on our Return-to-Growth Action Plan going deeper, moving faster and being bolder to enhance the customer experience, strengthen commercial performance and optimize capital allocation."
• "Our restructuring program announced today will allow us to streamline operations, improve efficiency and support a more competitive cost structure, while our decision to eliminate the dividend will enable the redeployment of capital toward share repurchases and debt reduction. These are important steps in our roadmap to drive sustained, profitable growth and deliver meaningful long-term value for our shareholders."
• "This decision reflects confidence in our growth outlook and disciplined focus on driving EPS growth, reducing share dilution, and capitalizing on what we believe is a share price that undervalues the long-term potential of Dentsply Sirona."

Industry Context

StockSavvy.ai notes that Dentsply Sirona's focus on 'connected dentistry' and strategic partnerships with major distributors like Patterson Dental aligns with broader industry trends towards integrated digital workflows and strengthened supply chain relationships in the dental sector. The launch of a new medical device, Surity Female External Catheter, indicates a strategic diversification beyond core dental products, potentially tapping into adjacent healthcare markets for growth.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Income-focused shareholders are impacted by the dividend elimination, but the new capital allocation strategy aims for long-term value creation through debt reduction and share repurchases.
• Employees: The restructuring plan may involve workforce adjustments, though the company plans to reinvest in sales team education.
• Customers: Increased investment in accelerated innovation and clinical education is intended to enhance product offerings and customer experience.
• Creditors: The strategy to redeploy capital towards debt retirement is expected to strengthen the balance sheet and potentially improve creditworthiness.
• Suppliers/Partners: New agreements with key dental distributors (Patterson, Benco, Burkhart, A-dec) strengthen commercial relationships and distribution channels.

Next Steps

• Implement the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistry.
• Incur non-recurring charges in the approximate range of $55 million to $65 million for the restructuring plan, with the majority expensed and paid in cash in 2026 and 2027.
• Redeploy capital towards debt retirement and share repurchases following the elimination of the quarterly cash dividend.
• Host an investor conference call and live webcast on February 26, 2026, at 4:30 pm ET to discuss these results and outlook.

Key Dates

Recommendation

The company is undergoing a significant strategic pivot with a restructuring plan and a new capital allocation strategy, including dividend elimination. While Q4 showed some positive sales momentum and adjusted EBITDA growth, the full-year performance was weak, marked by substantial impairments. The 2026 outlook is modest. The long-term benefits of these strategic changes are yet to materialize, making it a 'hold' as investors await clearer signs of sustained profitable growth and successful execution of the Return-to-Growth Action Plan.

Keywords

Dentsply Sirona, XRAY, Dental Products, Financial Results, Q4 2025, FY 2025, 2026 Outlook, Restructuring, Capital Allocation, Dividend Elimination, Share Repurchases, Debt Reduction, Goodwill Impairment, Adjusted EPS, Net Sales, Connected Dentistry, Medical Devices, Corporate Governance